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The winged-helix transcription factor Foxa2
regulatesPdx1 gene expression and fetal endo-
crine pancreas development. We show here by
inducible gene ablation that Foxa2 inactivation
in mature b cells induces hyperinsulinemic
hypoglycemia in Foxa2loxP/loxP,Pdx1-CreERT2
adult mice. Mutant b cells exhibited a markedly
increased pool of docked insulin granules,
some of which were engaged in sequential
or compound exocytosis, consistent with in-
creased first-phase glucose-stimulated insulin
secretion. Expression of multiple genes in-
volved in vesicular trafficking, membrane tar-
geting, and fuel-secretion pathways is depen-
dent on Foxa2. In addition, impaired cytosolic
Ca2+ oscillations and elevated intracellular
cyclic AMP production accompanied this se-
cretory defect and were likely contributors to
the sensitization of the exocytotic machinery.
Thus, in the absence of Foxa2, alterations in
intracellular second-messenger signaling re-
distribute the insulin granules into the readily
releasable pool. We conclude that Foxa2 is
required for both fetal pancreas development
and the function of mature b cells.
INTRODUCTION
Tightly controlled insulin secretion by the b cell is critical
to the maintenance of energy homeostasis. b cells must
adjust insulin output to the prevailing blood sugar level
to promote glucose storage and prevent glycogen break-
down. Precise regulation of the insulin secretory response
is a finely tuned process requiring the participation of nu-
merous factors in glucose sensing, metabolism-secretion
coupling, and granule exocytosis (MacDonald et al.,
2005). The secretory response to acute glucose stimula-Cell Mtion begins with a first phase of rapid insulin release that
occurs promptly after exposure to glucose. This rapid
insulin secretion involves the ATP-sensitive K+ channel-
dependent pathway that raises cytosolic Ca2+ concentra-
tion, leading to immediate discharge of insulin granules
that are docked at the cell surface and primed for release
(Daniel et al., 1999). The subsequent second phase of
insulin secretion requires priming of additional docked
granules for fusion competence and for mobilization of
granules from reserve pools (MacDonald et al., 2005).
Cytoplasmic Ca2+ is the most important triggering sig-
nal for the exocytotic machinery in both phases of insulin
secretion. However, rising cyclic AMP (cAMP) levels or
increasing protein kinase A (PKA) activity, for instance in
response to the incretin GLP-1, augment insulin secretion
even in the absence of elevated Ca2+ (Komatsu et al.,
1995). Recent studies further suggest that these two intra-
cellular messengers (Ca2+ and cAMP) are interlinked and
reinforce each other (Dyachok et al., 2006).
The forkhead box a2 (Foxa2) gene is the founding mem-
ber of the mammalian forkhead transcription factor gene
family and plays important roles in fetal development
(Friedman and Kaestner, 2006). Mice homozygous for
a Foxa2 null mutation die shortly after gastrulation with
a disorganized node, absence of the notochord, and se-
vere defects in foregut morphogenesis (Ang and Rossant,
1994; Weinstein et al., 1994). In collaboration with Foxa1,
Foxa2 is essential for liver organogenesis (Lee et al.,
2005a) and to pattern the lung (Wan et al., 2005). In addi-
tion to its role in embryonic development, Foxa2 also
integrates the metabolic response of adult hepatocytes
to fasting (Zhang et al., 2005). Thus, Foxa2 is a critical
component for both organ development and function in
vertebrates.
The expression of Foxa2 in the pancreatic primordium
precedes pancreas morphogenesis (Lee et al., 2005b)
and persists in all endoderm-derived epithelial cell types
of the organ throughout development and adulthood.
Conditional inactivation of Foxa2 in early pancreatic epi-
thelial precursors prevents terminal differentiation of
a cells (Lee et al., 2005b), while ablation of Foxa2 in fetal
b cells affects islet morphology and secretory function,etabolism 6, 267–279, October 2007 ª2007 Elsevier Inc. 267
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due to hypoglycemia (Sund et al., 2001). These studies
have demonstrated that Foxa2 plays a critical role in the
differentiation of fetal pancreatic a and b cells. However,
it was still unclear whether Foxa2 plays a role in adult pan-
creatic endocrine cells. The present study demonstrates
that Foxa2 is essential for the physiology of mature b cells,
the oscillation of nutrient-stimulated Ca2+, and, surpris-
ingly, the machinery of insulin exocytosis.
RESULTS
Foxa2 Ablation in Adult b Cells
We employed conditional gene ablation to inactivate
Foxa2 in mature b cells. We bred Foxa2loxP/loxP mice to
Pdx1-CreERT2 transgenic mice (Figure 1A), in which
expression of a tamoxifen-inducible Cre recombinase
estrogen receptor fusion protein is driven by the Pdx1
promoter (Gu et al., 2002). The resulting Foxa2loxP/+,
Pdx1-CreERT2 mice were mated to Foxa2loxP/loxP mice
to obtain Foxa2loxP/loxP,Pdx1-CreERT2 mice, as well as
control Foxa2loxP/+,Pdx1-CreERT2, Foxa2loxP/loxP, and
Foxa2loxP/+ littermates.
Cre activity was induced in 8- to 10-week-old
Foxa2loxP/loxP control and Foxa2loxP/loxP,Pdx1-CreERT2
mice by administrating tamoxifen through subcutaneous
implantation of tamoxifen pellets. After 3 weeks of
tamoxifen treatment, we assessed the efficiency of
Foxa2 gene ablation on the mRNA and protein level.
Foxa2mRNA expression was reduced by 75% in pancre-
atic islets isolated from tamoxifen-treated Foxa2loxP/loxP,
Pdx1-CreERT2 mice as compared to tamoxifen-treated
Foxa2loxP/loxP or untreated Foxa2loxP/loxP,Pdx1-CreERT2
mice (Figure 1B). Immunostaining of pancreatic sections
for insulin and Foxa2 (Figures 1C–1H) demonstrated
Foxa2 deletion in 80%–85% of b cells in mutant islets
(Figures 1G and 1H), while all control b cells showed nu-
clear Foxa2 staining (Figures 1D and 1E). Notably, within
Foxa2loxP/loxP,Pdx1-CreERT2 islets, non-b cells (arrows in
Figure 1H) retained Foxa2, indicating that Cre-mediated
gene deletion was specific to b cells. The presence of
Foxa2 in non-b cells also explains the fact that Foxa2
mRNA expression is reduced by only 75% in whole islets,
because a, d, and PP cells contribute to Foxa2 mRNA
levels as well. Mutant islets maintained normal morphol-
ogy and architecture even after 3 weeks of tamoxifen
treatment (Figures 1F–1H). This finding contrasts with our
previous observations on Foxa2 deletion during fetal
development in the Foxa2loxP/loxP,RIP-Cre model, where
islet morphology is disrupted, with a cells intermixed into
the islet core (Sund et al., 2001). Thus, Foxa2 is required
for normal islet architecture only during development, but
not once islets have matured.
Foxa2 Deletion Occurs Exclusively in b Cells
Within the normal adult pancreas, all epithelial cell line-
ages in both the endocrine and exocrine compartments
express Foxa2. Foxa2 is essential for the terminal differen-
tiation of the glucagon-producing pancreatic a cells268 Cell Metabolism 6, 267–279, October 2007 ª2007 Elsevier(Lee et al., 2005b). Given that the Pdx1 promoter is active
in all epithelial cell precursors during early pancreas devel-
opment, leakiness of the promoter activity could result in
deleting the Foxa2 gene in non-b cells. We stained for
Foxa2 along with markers of other pancreatic cell types.
We found that in tamoxifen-treatedmutant islets, all a cells
coexpressed glucagon and Foxa2 (Figure 1J), and the
localization of a cells was the same within control and
mutant islets (Figure 1I and 1J). Likewise, Foxa2 expres-
sion was unaffected in somatostatin-producing d cells of
the mutant islets (Figure 1K) and in the acinar (Figure 1L)
and ductal cells (Figure 1M) of the exocrine pancreas.
Thus, any abnormal phenotype in tamoxifen-treated
Foxa2loxP/loxP,Pdx1-CreERT2 mice is due to Foxa2 func-
tion in mature b cells.
Foxa2 Deficiency in Adult b Cells Induces
Hyperinsulinemic Hypoglycemia
Although efficient deletion was achieved in both female
and male mutant mice, only male mice were used for
experiments because tamoxifen treatment alone caused
slight glucose intolerance in control females (data not
shown). Tamoxifen treatment of male control mice had
no significant effect on fed or fasted blood glucose levels
(Figure 2A). In contrast to control littermates, tamoxifen-
treated mutant mice showed a significant reduction in
blood glucose levels under both fed and fasted conditions
(Figure 2A; p < 0.01). The decrease in blood glucose in
these mutant mice was also significant when compared
to the same animals prior to tamoxifen exposure
(Figure 2A; p < 0.01). We performed glucose tolerance
tests on Foxa2loxP/loxP,Pdx1-CreERT2 mice and control
mice to assess the dynamic response of the mutant
animals to glucose. Foxa2loxP/loxP,Pdx1-CreERT2 mice
displayed a normal glucose tolerance profile that closely
resembled controls before tamoxifen treatment (Figure
2B). After tamoxifen treatment, however, Foxa2loxP/loxP,
Pdx1-CreERT2 mice exhibited significantly lower glucose
levels when compared to their pre-tamoxifen treatment
glucose response (Figure 2B; black diamonds versus
white diamonds, p < 0.01).
To examine the cause of hypoglycemia in Foxa2loxP/loxP,
Pdx1-CreERT2 mice, plasma insulin levels were deter-
mined after overnight fast and 2 hr refeeding. Plasma
insulin levels of tamoxifen-treated fed mutant mice were
more than 2-fold higher than those of tamoxifen-treated
controls (Figure 2C). The fasting insulin levels of mutant
micewere equivalent to controls, indicating that the b cells
in Foxa2 mutants retained some degree of control over
insulin secretion at low blood glucose levels (0 time point
in Figure 3A). In addition, Foxa2-deficient mice showed
significantly increased plasma glucagon levels under fed
and fasted conditions (Figure 2D), reflecting a normal
physiological response by a cells to hypoglycemia.
To determine whether alterations in insulin storage con-
tribute to hyperinsulinemia in Foxa2-deficient mice, total
pancreatic insulin content was measured. Surprisingly,
while glucagon content was equivalent between mutant
and control mice (Figure 2E), insulin levels in mutantInc.
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Foxa2 and Insulin SecretionFigure 1. Foxa2 Ablation in Mature b Cells
TM, tamoxifen; L/L, loxP/loxP.
(A) Adult Foxa2loxP/loxP,Pdx1-CreERT2 mice were administered tamoxifen to induce b cell-specific Foxa2 deletion.
(B) Quantitative RT-PCR showed significant reduction of Foxa2 mRNA levels in tamoxifen-treated Foxa2loxP/loxP,Pdx1-CreERT2 mouse islets.
**p < 0.01. In this and all subsequent figures, error bars represent SEM.
(C–H) Pancreas sections from tamoxifen-treated mice of the indicated genotypes were double stained with insulin (green) and Foxa2 (red) antibodies.
All control b cells expressed Foxa2 (C–E), while 80%–85% of b cells in Foxa2loxP/loxP,Pdx1-CreERT2 islets lacked Foxa2 nuclear staining (F–H). White
arrows in (H) denote insulin-negative (i.e., non-b) cells with nuclear Foxa2 staining.
(I and J) Pancreas sections were stained with glucagon (green) and Foxa2 (red). Broken lines circle islets of Langerhans.
(K–M) Mutant pancreas sections were stained with somatostatin (green) and Foxa2 (red) (K), amylase (green) and Foxa2 (red) (L), and lectin DBA (red)
and Foxa2 (green) (M).Cell Metabolism 6, 267–279, October 2007 ª2007 Elsevier Inc. 269
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Foxa2 and Insulin SecretionFigure 2. Mice Deficient for Foxa2 in Mature b Cells Develop Hyperinsulinemic Hypoglycemia
(A) Fed and fasting blood glucose levels of control (L/L) and mutant (L/L,cre) mice were measured under tamoxifen (TM)-treated and untreated
conditions. n = 5 for each group. **p < 0.01.
(B) Glucose tolerance test for tamoxifen-treated and untreated control and mutant mice. n = 6 for each group.
(C) Plasma insulin levels after 2 hr of refeeding.
(D) Plasma glucagon levels under fasted conditions and after 2 hr of refeeding.
(E) Pancreatic glucagon content.
(F) Pancreatic insulin content.
(G) b cell mass determination. n = 4 control and 5 tamoxifen-treated Foxa2 mutant animals.
(H) Quantification of a cell numbers. Data shown represent the average a cell number per islet. n = 4 tamoxifen-treated animals of each genotype.
(I) Quantitative RT-PCR of Ins1, Ins2, and glucagon (Gcg) mRNA levels in tamoxifen-treated control and Foxa2-deficient islets. *p < 0.05; **p < 0.01;
***p < 0.001.pancreata were significantly lower (Figure 2F). Since the
b cell mass of Foxa2 mutant pancreata was not signifi-
cantly different from that of controls (Figure 2G), this
decrease in insulin stores in Foxa2-deficient b cells is likely
caused by abnormally increased insulin secretion. This270 Cell Metabolism 6, 267–279, October 2007 ª2007 Elseviernotion was supported by the fact that Foxa2-deficient
b cells proliferated normally as determined by BrdU incor-
poration (data not shown). Likewise, no difference in the
apoptotic rate of Foxa2-deficent b cells was found as
assessed by TUNEL assay (data not shown). In addition,Inc.
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Foxa2 and Insulin SecretionFigure 3. Increased Insulin Secretion by
Foxa2-Deficient b Cells
Control islets (L/L) are shown in squares and
mutant islets (L/L,cre) in diamonds.
(A) Plasma insulin levels of tamoxifen-treated
control and mutant mice following glucose
challenge. n = 5 for both groups.
(B) Corresponding blood glucose levels of
animals in (A).
(C) Perifusion assay of islets isolated from
tamoxifen-treated control and mutant mice. A
glucose ramp (0–50 mM) with an increasing
rate of 1.25 mM/min is indicated. Control islets
showed a biphasic insulin secretory response,
whilemutants showed amuch stronger, mono-
phasic response. Addition of 30mMpotassium
chloride (KCl) at the end of perifusion elicited
the maximum insulin secretory response. n = 3
independent experiments for each genotype.
(D) Perifusion assay of islets from tamoxifen-
treated control and mutant mice, with KCl
added to elicit maximum insulin output. KCl
was withdrawn after 10 min.we did not identify a significant difference in a cell
numbers between control and mutant islets (Figure 2H).
Finally, a defect in insulin gene transcription could not
account for the major difference in insulin content since
Ins2 mRNA levels were only slightly decreased and Ins1
mRNA levels were unchanged in Foxa2loxP/loxP,Pdx1-
CreERT2 mouse islets (Figure 2I).
Increased Insulin Secretion in Foxa2-Deficient
Adult b Cells
To determine whether Foxa2-deficient adult b cells
secrete abnormal amounts of insulin, we measured
plasma insulin levels at various time points following a glu-
cose challenge. Mice were fasted overnight and injected
intraperitoneally with glucose. The same dose of glucoseCellelicited a far greater increase in plasma insulin levels in
mutant mice than in controls (Figure 3A), corresponding
to a more rapid decrease of blood glucose levels in
mutants 10 min after glucose injection (Figure 3B). To
directly assess insulin secretion in vitro, we performed
perifusion assays on pancreatic islets isolated from
mutant and control mice. Mutant islets produced a basal
insulin level similar to control islets (Figure 3C). Although
5 mM glucose initiated insulin secretion in both control
and mutant islets, the secretory response produced by
mutant islets wasmuchmore pronounced, with amaximal
10-fold increase over baseline, as compared to a 5-fold
increase by the control islets (Figure 3C). After glucose
withdrawal, 14 min were required for mutant islets to re-
duce insulin secretion to baseline, in contrast to a 5 minMetabolism 6, 267–279, October 2007 ª2007 Elsevier Inc. 271
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Foxa2 and Insulin Secretiontermination period in control islets. Nevertheless, mutant
islets displayed a good termination response (Figure 3C),
indicated by a 1.32 ng/min off rate in the first 5 min follow-
ing glucose withdrawal and a 0.1 ng/min rate in the follow-
ing 8min. The off rates of control islets were 0.46 ng/min in
the first 5 min and 0.001 ng/min in the following 8 min. We
stimulated islets with 30 mM KCl to evaluate the maximal
insulin output. Both control and mutant islets responded
to KCl by robustly secreting insulin, but overall, the control
islets secreted more insulin than mutant islets (Figure 3D),
consistent with the reduced insulin content in mutant
pancreata described above (Figure 2F).
Expression Profile of Foxa2-Deficient Mature
b Cells
Mechanisms that couple glucose metabolism to insulin
secretion include the generation of metabolic signals,
alteration ofmembrane potential, and exocytosis of insulin
vesicles (Bratanova-Tochkova et al., 2002; MacDonald
et al., 2005). In order to understand the phenotype of
Foxa2-deficient b cells, we employed cDNA microarray
analysis on islet samples from tamoxifen-treated mutant
and control mice. We identified 143 genes with signifi-
cantly altered mRNA levels in mutant islets (see Table S1
in the Supplemental Data available with this article online).
We compared our data with a previous microarray study
that analyzed Foxa2loxP/loxP,RIP-Cre mouse islets, in
which Foxa2 was deleted in fetal b cells (Lantz et al.,
2004). Although different microarray platforms were
used in the two studies and although the previous exper-
iment was performed on newborn instead of adult islets,
about 40% of the previously identified Foxa2 targets
were found to be regulated by Foxa2 in the mature b cell
as well, with remarkably similar fold changes (Table S2).
In contrast, the current study revealed over 100 novel
Foxa2 targets, which is likely a reflection of the more
elaborate glucose sensing and insulin secretion machin-
ery operating in the mature b cell (Table S1).
We systematically examined the expression levels of
potassium and calcium channel-encoding genes. The ex-
pression of Kir6.2 and Sur1, two known Foxa2-regulated
genes that encode subunits of the ATP-dependent K+
channel, was reduced as determined by quantitative RT-
PCR, confirming previous reports (Lantz and Kaestner,
2005; Sund et al., 2001; Wang et al., 2002). In addition,
the mRNA level of Kcnb1, a voltage-gated K+ channel,
was significantly reduced in mutant islets (Figure 4A).
We did not detect significant changes in the L-type volt-
age-dependent calcium channels (Cacna1c andCacna1d)
or the R-, T-, and P/Q-type calcium channels. Likewise, no
difference was seen in calcium channels expressed on
the endoplasmic reticulum membrane (Figure 4A).
Expression of the type II voltage-gated sodium channel
b subunit (Scn2b) and glucose transporter 5 (Glut5) was
significantly upregulated, while G protein-coupled recep-
tor 43 (GPR43), also known as free fatty acid receptor 2
(Ffar2), was significantly downregulated (Figure 4A; Table
S1) in Foxa2-deficient islets. In contrast, the expression of
glucose transporter 2 (Glut2) was unchanged. Given the272 Cell Metabolism 6, 267–279, October 2007 ª2007 Elsevierhigh glucose transport capacity of Glut2, the increase in
Glut5 expression is not likely to affect the equilibration of
glucose across the plasma membrane of b cells. The
role of GPR43 in pancreatic islets is still unclear; however,
its paralog, GPR40, has been shown to be necessary for
fatty acid stimulation of insulin secretion (Latour et al.,
2007).
Expression of several genes encoding metabolic en-
zymes was significantly altered in mutant islets, including
short-chain L-3-hydroxyacyl-coenzyme Adehydrogenase
(Hadhsc), dopa decarboxylase (Ddc), deoxycytidine
kinase (Dck), and pyruvate dehydrogenase kinase 1
(Pdk1) (Figure 4B). Reduction in Hadhsc expression in
b cells leads to increased basal insulin secretion rates
(Hardy et al., 2007), consistent with the finding that hetero-
zygosity for HADHSC mutations can cause hyperinsulin-
ism in children (Clayton et al., 2001; Molven et al., 2004),
and thus likely contributes to the hypersecretion pheno-
type in Foxa2-deficient b cells.
We had previously shown that Foxa2 is required for full
activation of thePdx1 locus in pancreatic b cells (Lee et al.,
2002). This requirement is maintained even in mature
b cells, where the transcriptional regulatory network has
been fully established, as Pdx1 mRNA levels were
reduced by >70% when Foxa2 was deleted in the mature
b cell (Figure 4C). Most of the remaining transcription
factor network was stable in the absence of Foxa2, with
the exception of HNF4a, which was significantly upregu-
lated. Other altered genes included nuclear receptor-
interacting protein 1 (Nrip1), SHP, CREB, and PGC-1a
(Figure 4D), indicating that Foxa2 regulates a limited set
of transcription factors in mature b cells.
Among the novel Foxa2 targets in b cells, we found
a number of genes with known or putative functions in
intracellular granule biosynthesis, vesicle trafficking, and
exocytosis (Figure 4E; Table S1). Among these factors,
chromogranin B (ChgB) is thought to be critical for secre-
tory granule biogenesis in neuroendocrine cells (Huh et al.,
2003).Mtac2d1 (membrane targeting [tandem] C2 domain
containing 1) contains the C2 domain also found in mam-
malian Ca2+-dependent protein kinase C isoforms and
numerous other proteins involved in vesicular trafficking
(Fukuda andMikoshiba, 2001).Myh10 is a nonmuscle iso-
form of myosin heavy chain, whose family memberMyh12
(or MYO5A) transports dense-core secretory vesicles in
MIN6 insulinoma cells (Varadi et al., 2005). Vesicle-associ-
ated membrane protein-associated protein B (Vapb)
encodes a type IV membrane protein found in plasma
and intracellular vesicle membranes that interacts with
VAMP1 and VAMP2, two vesicular soluble N-ethylmalei-
mide-sensitive factor attachment protein receptor
(v-SNARE) proteins (Nishimura et al., 1999). RAS guanyl
releasing protein 1 (Rasgrp1) encodes a member of an
emerging family of exchange factors for Ras family
GTPases; proteins in this family are able tomediate effects
of second messengers in a protein-kinase-independent
fashion (Springett et al., 2004). Rab6 encodes a small
GTP-binding protein associated with secretory granules
in several other cell types (Iida et al., 1997). The elevatedInc.
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Foxa2 and Insulin SecretionFigure 4. Quantitative RT-PCR
mRNA levels of the indicated genes were determined by real-time RT-PCR of total RNA isolated from islets of tamoxifen-treated control (L/L) or
mutant (L/L,cre) animals. Genes shown with vertical shading were predicted by microarray analysis to be significantly changed. *p < 0.05; **p < 0.01.
(A) Genes encoding ion channels, transporters, and receptors.
(B) Genes encoding enzymes and metabolism-secretion coupling factors.
(C) Maturity onset diabetes of the young (MODY) genes.
(D) Transcription factors.
(E) Genes with known or putative functions in granule dynamics and exocytosis.expression of all of these genes suggests an alteration in
vesicular movement and exocytosis (Table S1) in Foxa2-
deficient b cells.
Impaired Ca2+ Oscillation in Foxa2-Deficient
b Cells
Cytosolic Ca2+ and cAMP are themost critical intracellular
second messengers that regulate the exocytotic machin-
ery of the b cell. Elevated cytosolic Ca2+ concentrations
have been described in hyperinsulinemic models such
as Kir6.2 and Sur1 knockout mice (Miki et al., 1998; Shiota
et al., 2002). Ca2+ imaging analysis showed that the base-
line of Ca2+ levels in Foxa2-deficient islets was the same
as in controls, and at the concentrations tested, the
glucose threshold was not changed in mutant islets
(Figure 5A). The elevation of intracellular Ca2+ in mutant
islets following 8 mM glucose stimulation was lower than
that of control islets (Figure 5A). Moreover, Ca2+ concen-
trations in mutant islets barely responded to additional
stimulation by 16 mM glucose. In contrast, control islets
responded strongly to 16 mM glucose with a greater spikeCell Mof Ca2+ (Figure 5A). In spite of lower cytosolic Ca2+ con-
centrations upon glucose stimulation, mutant islets
showed sustained elevation of cytosolic Ca2+ even after
glucose withdrawal, while in control islets, Ca2+ levels
dropped immediately after removal of glucose
(Figure 5A). Intriguingly, the oscillations of cytosolic Ca2+
concentration in mutant islets were significantly dimin-
ished, in sharp contrast to the strongly synchronized
oscillations in control islets (Figures 5B and 5C).
Intracellular cAMP levels in mutant and control islets
were measured by ELISA. Foxa2-deficient islets showed
a significantly higher basal cAMP level at 3 mM glucose,
while cAMP levels at 16 mM glucose were similar to
control islets (Figure 5D).
Docked Insulin Granules Are Increased
in Foxa2-Deficient b Cells
The expression profiling detailed above pointed to a dys-
function in vesicular movement or insulin exocytosis in
Foxa2-deficient b cells as the most likely explanation for
the severe insulin secretory defect. Since the number ofetabolism 6, 267–279, October 2007 ª2007 Elsevier Inc. 273
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Foxa2 and Insulin SecretionFigure 5. Altered Intracellular Messen-
gers in Mutant Islets
(A) Cytosolic Ca2+ imaging was performed on
tamoxifen-treated control (L/L) and mutant
(L/L,cre) islets at glucose (G) levels described
in Experimental Procedures. KCl (30 mM) was
used to elicit the maximal Ca2+ response. The
basal Ca2+ concentration was 108.8 ± 0.4 nM
in control islets and 113.1 ± 1.0 nM in mutant
islets. At 8mMglucose, the peak Ca2+ concen-
tration was 633.7 ± 45.5 nM in control islets
and 343.3 ± 13.5 nM in mutant islets (p <
0.001). At 16 mM glucose, the peak Ca2+ con-
centration was 998.7 ± 122.7 nM in control is-
lets and 396.3 ± 25 nM in mutant islets (p <
0.001). After glucose withdrawal, the Ca2+ con-
centration returned to 139.7 ± 5.5 nM in control
islets and 212.8 ± 15.2 nM in mutant islets (p <
0.001). Data shown are representative of three
independent experiments for each genotype.
(B and C) Ca2+ oscillations at 8 mM and 16 mM
glucose concentrations. Color traces repre-
sent noncontiguous regions of the same islet.
Note that the Ca2+ oscillations are highly syn-
chronized in control islets (B) but not in
Foxa2-deficient islets (C).
(D) Intracellular cAMP levels in tamoxifen-treated
control and mutant islets incubated in Krebs
buffer with 3 mM or 16 mM glucose. *p < 0.05.docked and primed insulin granules is amajor determinant
of the magnitude of the initial secretory response (Daniel
et al., 1999), the enhanced first-phase insulin secretion
by mutant b cells suggested an increase in the granule
pool readily available for rapid release. Indeed, electron
microscopy detected a greater number of granules lining
the plasma membrane of mutant b cells compared to
controls (Figures 6A, 6B, 6D, and 6E). Vesicles in control
b cells were largely scattered throughout the cytoplasm,
with only a few docked at the plasma membrane (Figures
6A and 6B), consistent with previous reports in normal
b cells (Straub et al., 2004). Strikingly, in addition to the in-
creased accumulation of vesicles in the peripheral regions
of Foxa2-deficient b cells (compare Figures 6F and 6C),
a large number of vesicles in mutant b cells appeared to
be docking to adjacent vesicles in addition to those that274 Cell Metabolism 6, 267–279, October 2007 ª2007 Elsevierwere fusing to the plasmamembrane (marked by asterisks
in Figure 6D), while vesicles in control cells were sepa-
rated from each other (Figure 6A). These data suggest
an increase in sequential exocytosis, a process in which
a secretory granule fuses with another granule already
docked at the plasma membrane instead of fusing with
the plasma membrane directly (Kwan and Gaisano,
2005). Finally, the vesicles in mutant b cells showed
a higher level of heterogeneity, with an increased fraction
of apparently ‘‘empty’’ vesicles (Figures 6D and 6F) than
seen in control b cells (Figures 6A and 6C). Quantification
of the diameters of vesicles showed a highly significant
increase in vesicle size in Foxa2 mutant b cells (Figure 6G),
supporting theapparentpremature fusionof insulingranules.
To quantify the docked granule pool, we utilized coim-
munoprecipitation analysis of the t-SNARE proteinInc.
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Foxa2 and Insulin SecretionFigure 6. Electron Microscopy of Control and Foxa2-Deficient b Cells
(A and B) Only a few vesicles are docked at the intercellular plasma membranes of adjacently localized control b cells (A) or at plasma membranes
adjacent to capillaries (B). Broken red line in (A) marks plasma membrane; arrows in (B) indicate docking insulin granules. cp, capillary.
(C) Control b cells show homogeneous insulin granules with scattered distribution throughout the cytoplasm.
(D) Accumulation of insulin vesicles at or near the plasma membranes in a mutant b cell. Asterisks mark vesicles that appear to have fused with each
other.
(E) Increased docking of insulin granules (arrows) on a mutant b cell plasma membrane adjacent to a capillary.
(F) Foxa2-deficient b cells contain vesicles with greater heterogeneity, accumulating at peripheral regions of the cells.
(G) Vesicle diameter in mutant b cells is significantly larger than in control cells. ***p < 0.0001.
Scale bars = 500 nm in (B), (D), and (E); 2 mm in (C) and (F).syntaxin and the v-SNARE protein VAMP2, the interaction
of which correlates to vesicle-to-membrane docking
(Daniel et al., 1999). Western blot analysis indicated that
the total cellular protein levels of VAMP2, SNAP25, and
syntaxin were equivalent between control and mutant
islets when normalized to the levels of two control pro-
teins, Glut2 and tubulin (Figure 7A). Immunoprecipitation
of syntaxin followed by western blot detection of
VAMP2 and SNAP25 demonstrated an enrichment of
these SNARE components in mutant islets (VAMP2,
1.66-fold increase; SNAP25, 1.44-fold increase). Immu-
noprecipitation of VAMP2 followed by western blot
analysis of syntaxin also suggested a 1.65-fold increase
of syntaxin and VAMP2 interaction in the mutant lysates
(Figure 7A).
The distribution of insulin-containing granule vesicles
was analyzed by confocal immunofluorescence micros-
copy. In contrast to control b cells, a significantly larger
fraction (1.7-fold increase; p < 0.05, n = 3) of insulin vesi-
cles (marked by VAMP2 or insulin) in mutant b cells wereCell Mlocalized at or near the plasma membrane (marked by
Glut2) (Figures 7B and 7C). These observations collec-
tively suggested an increased vesicle-plasma membrane
interaction in Foxa2-deficient b cells. This increase in the
membrane-docked readily releasable insulin granule
pool and in sequential exocytosis, which is likely driven
by the changes in both the cAMP levels and the vesicle
trafficking machinery discussed earlier, provides an
explanation for the abnormal first-phase insulin secretory
response observed in the Foxa2loxP/loxP,Pdx1-CreERT2
model.
DISCUSSION
Regulation of Mature b Cell Function by Foxa2
Master regulators such as Foxa2 direct the expression of
downstream factors that are responsible for cell lineage
establishment. In the pancreatic primordium, Foxa2 regu-
lates the expression of Pdx1 (Lee et al., 2002; Wu et al.,
1997) and Maf-A (Raum et al., 2006), two importantetabolism 6, 267–279, October 2007 ª2007 Elsevier Inc. 275
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Foxa2 and Insulin SecretionFigure 7. Increased Vesicle-Plasma
Membrane Interactions in Foxa2-Defi-
cient b Cells
(A) Total islet lysates were immunoprecipitated
with anti-syntaxin antibody. Precipitates were
resolved in SDS-PAGE gels, and VAMP2,
SNAP25, and syntaxin were detected with
specific antibodies. Reverse experiments
were performed by immunoprecipitation with
VAMP2 antibody followed by western blotting
analysis of syntaxin. Equivalent VAMP2, syn-
taxin, and SNAP25 protein levels were de-
tected in total lysates from control and mutant
islets when normalized to Glut2 and tubulin
loading controls.
(B and C) The distribution of insulin granule
vesicles was analyzed by confocal microscopy
with insulin (B) and VAMP2 (C) antibodies (red)
labeling the vesicles andGlut2 antibody (green)
labeling the b cell plasmamembrane. Asterisks
mark capillaries. Magnifications of the low- and
high-power images are 2503 and 6303,
respectively.b cell transcription factors. In Foxa2-deficient mature
b cells, although Pdx1 expression is reduced, most of
the transcription factor network, includingMaf-A, remains
stable (Figure 4). These data support the notion that, in
mature b cells, Foxa2-regulated insulin secretion is a
function separated from its role in the transcription factor
cascade that governs b cell development and islet
architecture.
Our study suggests that Foxa2 regulates a number of
factors ranging from ion channels and metabolic enzymes
to proteins involved in granule exocytosis. In addition to
several previously known Foxa2-controlled genes, novel
Foxa2 targets include Mtac2d1, Chgb, and Vapb, which
may control insulin vesicle-to-membrane targeting, insulin
granule biogenesis, and SNARE protein interactions. A
recently identified microRNA has been found to regulate
Foxa2 expression in insulinoma cell lines (Baroukh et al.,
2007). Modulating this microRNA also affects multiple
Foxa2 targets while perturbing intracellular signaling in
the b cells.276 Cell Metabolism 6, 267–279, October 2007 ª2007 ElsevierFirst-Phase Insulin Secretion, Insulin Granule
Pools, Exocytosis, and Hyperinsulinism
Initial insulin release from normal islets is followed by
a rapid drop in secretion rate due to the fact that the num-
ber of membrane-docked readily releasable granules is
limited. Diabetes is marked by the deterioration of this first
phase of insulin secretion (Cerasi, 1975; Cerasi and Luft,
1967). Pancreatic islets from type 2 diabetic patients
show impaired expression of exocytotic SNARE proteins
(Ostenson et al., 2006), implying that defects in exocytosis
contribute to the secretory defects. Interestingly, SNARE
proteins are unchanged in Foxa2-deficient b cells despite
the fact that an increased fraction of insulin granules are
docked at the plasma membrane. These docked granules
were already primed for rapid secretion since glucose im-
mediately elicited an abnormally large insulin release. This
is significant considering that normally less than 1% of
insulin granules (<100) in a b cell are readily releasable
(Bratanova-Tochkova et al., 2002). The increased associ-
ation of VAMP2 and syntaxin proteins in Foxa2 mutantInc.
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Foxa2 and Insulin Secretionislets provides an explanation for the increased docking
vesicles in tamoxifen-treated Foxa2loxP/loxP,Pdx1-CreERT2
mice.
In Foxa2 mutant b cells, a large number of secretory
vesicles are fused with other vesicles before exocytosis.
This multivesicle fusion process has been described in
pancreatic b cells previously (Bokvist et al., 2000; Orci
and Malaisse, 1980; Takahashi and Kasai, 2007) and has
been distinguished in two forms, sequential exocytosis
and compound exocytosis (Kwan and Gaisano, 2005). In
sequential exocytosis, insulin granules fuse to vesicles
that have made contact to the plasma membrane instead
of fusing to the plasma membrane directly (Leung et al.,
2002), while in compound exocytosis, secretory granules
fuse before exocytosis (Bokvist et al., 2000). Rising
cAMP levels in b cells, in response to either glucagon-
like peptide 1 or forskolin treatment, increase both se-
quential and compound exocytosis (Kwan and Gaisano,
2005; Leung et al., 2002). These findings suggest a molec-
ular link between the increased cAMP concentrations
found in Foxa2 mutant islets and the increased frequency
of sequential/compound exocytosis observed in this
model.
Our findings support a model in which Foxa2 controls
multiple aspects of insulin secretion in mature b cells
through transcriptional regulation of genes involved in glu-
cose sensing, metabolism, and granule exocytosis, which
we summarize schematically in Figure S1. Thus, in addi-
tion to controlling fetal pancreas development, Foxa2
also plays a major role in the assembly and maintenance
of the glucose metabolism and insulin secretion machin-
ery in adult pancreatic b cells.
EXPERIMENTAL PROCEDURES
Mice
Foxa2loxP/loxP mice have been described previously (Sund et al., 2001).
Pdx1-CreERT2 mice were kindly provided by D. Melton (Harvard Uni-
versity). All mice were maintained on amixed 129SvEv/C57BL/6 back-
ground. Genotyping was performed by PCR using genomic DNA
isolated from the toe tips of newborn mice. Eight- to ten-week-old
adult male mice were used in all experiments.
To induce Foxa2 ablation, tamoxifen pellets (free base, 25mg/pellet,
21 day release, E-361; Innovative Research of America) were im-
planted subcutaneously into the mice. Analysis was performed after
3 weeks of implantation. Procedures involving mice were approved
by the University of Pennsylvania Institutional Animal Care and Use
Committee.
Determination of b Cell Mass and a Cell Number
Pancreata from four tamoxifen-treated Foxa2loxP/loxP control and five
Foxa2loxP/loxP,Pdx1-CreERT2 mutant mice were dissected, weighed,
flattened by forceps, fixed in 4% PFA, and paraffin embedded so
that tissues with the maximum pancreatic footprint were sectioned.
One section from each animal was immunostained for insulin using
the standard DAB method without counterstaining. The entire tissue
section was scanned using a laser capture microdissection micro-
scope to obtain a single 403 image, from which the percentage of
b cell area relative to the total pancreatic area was measured and cal-
culated using IPLab scientific image processing software (version
3.6.5, Scanalytics, Inc.). b cell mass was derived from the total pan-
creas weight multiplied by the percentage of b cell area. To estimate
a cell number, the total number of a cells was manually countedCell Mfrom an entire pancreatic section immunostained for glucagon. One
slide per animal was counted, and four animals were used for each
genotype. The average a cell number per islet was then calculated
for each animal.
For proliferation analysis, BrdU labeling was performed by intraper-
itoneal injection of 1 ml concentrated BrdU (#11-1013, Zymed Labora-
tories) per 100 g body weight. Pancreata were dissected 24 hr later,
fixed with 4% PFA, and double stained with anti-BrdU antibody from
the Zymed BrdU staining kit (#93-3943) and anti-insulin antibody. Islet
cells labeled with both insulin and BrdU were counted from sections of
three animals of each genotype. For apoptosis assay, staining was
performed using the ApopTag Plus Fluorescein In Situ Apoptosis De-
tection Kit (S7111, Chemicon) along with anti-insulin antibody to label
b cells. Apoptotic b cell number was counted from sections of three
animals of each genotype.
Immunofluorescence Analysis
Indirect immunofluorescence was performed using confocal micros-
copy (Leica Microsystems, Inc.). The primary antibodies used were
guinea pig anti-insulin (1:1000 dilution; Linco Research, Inc.), guinea
pig anti-glucagon (1:200; Linco Research, Inc.), rabbit anti-somato-
statin (1:50; Zymed Laboratories), rabbit anti-amylase (1:1000; Sigma),
rabbit and goat anti-Foxa2 (1:800) (Lee et al., 2005b), biotinylated
Dolichos biflorus agglutinin (DBA) (1:1000; Vector Laboratories), rabbit
anti-VAMP2 (1:500; Abcam), rabbit anti-Glut2 (1:300; Chemicon), and
goat anti-Glut2 (1:300; Santa Cruz). Cy3-, Cy5-, or Cy2-conjugated
donkey anti-rabbit, anti-guinea pig, and anti-goat IgGs were
purchased from Jackson ImmunoResearch Laboratories, Inc.
For colocalization analysis, images were acquired with no detect-
able saturation in each fluorescence channel. Percentage of colocali-
zation was calculated as number of overlapped pixels/number of total
pixels using Zeiss Laser Scanning Microscope software (version
3.2SP2). Three different sections from each genotype were used for
a two-tailed paired Student’s t test analysis.
Glucose Tolerance Tests and Hormone Assays
Animals were fasted overnight, and blood glucose levels were mea-
sured by Glucometer Elite (Bayer Corporation). Mice were then in-
jected intraperitoneally with 2 g of glucose (Sigma-Aldrich) per kg of
body weight. Glucose levels were measured at 15, 30, 60, 90, and
120 min postinjection. To determine plasma insulin levels during glu-
cose tolerance tests, mice fasted overnight were injected with 3 g of
glucose per kg of body weight, and blood was collected from the tail
vein 2, 5, 15, and 30 min after injection. Plasma and pancreatic insulin
and glucagon concentrations were measured by ELISA (Crystal Chem
Inc.) as described previously (Sund et al., 2001).
Islet Perifusion and Ca2+ Imaging
Islets were isolated frommutants and controls using standard collage-
nase digestion followed by purification through a Ficoll gradient (Gupta
et al., 2005). One hundred islets were hand picked under a light micro-
scope and placed into a perifusion chamber (Millipore). A computer-
controlled fast-performance HPLC system (625 LC System, Waters
Corporation) allowed programmable rates of flow and concentration
of the appropriate solutions held in a 37Cwater bath. Islets were peri-
fused with Krebs bicarbonate buffer (2.2 mM Ca2+, 0.25% bovine se-
rum albumin, 10 mM HEPES, and 95% O2/5% CO2 equilibration [pH
7.35]) to reach baseline hormone secretion values before the addition
of the appropriate secretagogues. Samples were collected at regular
intervals with a fraction collector (Waters Corporation). Insulin content
was determined using a radioimmunoassay (University of Pennsylva-
nia Diabetes Center). Ca2+ measurement was performed as described
previously (Doliba et al., 2006).
cAMP Measurement
Freshly isolated islets were washed twice with Hank’s buffer and incu-
bated at 37C for 45 min in Krebs-Henseleit buffer with 2.2 mmol/l
Ca2+, 0.25% BSA, and 0 mM glucose. Islets were then transferred toetabolism 6, 267–279, October 2007 ª2007 Elsevier Inc. 277
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Fifty islets were used for each cAMP measurement. Measurements
were performed in triplicate for each genotype. Intracellular cAMP
measurement was performed using the nonacetylation enzyme immu-
noassay procedure (RPN225, Amersham Biosciences).
Microarray and Quantitative Real-Time PCR
Islets were isolated using standard collagenase procedure as de-
scribed above. Total RNA from islets was extracted in TRIzol (Invitro-
gen) according to the manufacturer’s instructions. Islet purity was as-
sessed so that pairs of control and mutant RNA samples with similar
purity werematched (Lantz et al., 2004). Six pairs of control andmutant
islet RNA samples were obtained. Fifty nanograms of each RNA sam-
ple was amplified using the Ovation Aminoallyl RNA Amplification and
Labeling System (NuGEN Technologies, Inc.) for microarray analysis
using PancChip 6.1 (http://www.betacell.org/ma/). Two hybridization
pairs were rejected due to poor hybridization quality. For real-time
PCR, RNA was reverse transcribed using 1 mg oligo(dT) primer, Super-
Script II Reverse Transcriptase, and accompanying reagents (Invitro-
gen). PCR reaction mixes were assembled using Brilliant SYBR Green
QPCR Master Mix (Stratagene). Reactions were performed using the
SYBR Green (with dissociation curve) program on a Mx4000 Multiplex
Quantitative PCR System (Stratagene). All reactions were performed in
triplicate with reference dye normalization, and median cycling thresh-
old values were used for analysis. Primer sequences are available at
http://www.med.upenn.edu/kaestnerlab/index.shtml.
Coimmunoprecipitation and Western Blotting
Islets were isolated; pooled according to genotype (six mice for each
genotype); and lysed in lysis buffer containing 50 mM Tris (pH 7.5),
150 mM NaCl, 10 mM EDTA, 0.02% NaN3, 50 mM NaF, 1 mM
Na3VO4, 1% NP40, 1 mM PMSF, and protease inhibitors (Sigma).
0.5 mg total protein lysates were incubated at 4C for 6 hr with 20 ml
protein G Sepharose beads conjugated with anti-syntaxin (Abcam)
or anti-VAMP2 antibody (Abcam). Beads were then washed twice
with lysis buffer and once with PBS, heated at 70C for 10 min in 43
LDS buffer (Invitrogen), and loaded on 4%–12% SDS-PAGE (Invitro-
gen). Proteins were transferred to PVDF membranes (Invitrogen) and
detected by antibodies against VAMP2 (1:1000, Abcam), syntaxin
(1:500, Abcam), SNAP25 (1:2000, Abcam), Glut2 (1:1000, Chemicon),
or tubulin (1:5000, Sigma). Membranes were stripped in western strip-
ping buffer (Pierce) and reprobed with corresponding antibodies.
Electron Microscopy
Fresh pancreata were washed with PBS and suspended in a fixative
solution of 2.5% cacodylate-buffered glutaraldehyde and 4% parafor-
maldehyde (pH 7.4) for 5 hr. Tissues were rinsed in a cacodylate-
buffered solution, postfixed with 2% cacodylate-buffered OsO4
dehydrated with graded ethanol, clarified in propylene oxide, and
embedded in Epon. Sections (70 nm) were obtained with a Leica
UCT ultramicrotome using a Diatome diamond knife and picked up
on 200-mesh copper grids. Sections were stainedwith an alcoholic so-
lution of uranyl acetate followed by a solution of bismuth subnitrate.
These sections were examined under a JEOL JEM1010 electron mi-
croscope, and digital images were captured using AMT Advantage
HR-aided Hamamatsu CCD camera. All EM supplies were purchased
from Electron Microscopy Sciences and Ted Pella, Inc. To quantify
vesicle diameter, the larger diameter of individual insulin vesicles
was measured by a point-to-point method using AMT Image Capture
Engine software (version 5.42.308). An unpaired Student’s t test was
performed on a total of 584 control and 349 mutant vesicles imaged
from three different animals of each genotype.
Supplemental Data
Supplemental Data include two tables and one figure and can be found
with this article online at http://www.cellmetabolism.org/cgi/content/
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